RCS - Hutchmed China Ltd - Data to be Presented at AACR Congress 2024
05/04/2024 09:30
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240405:nRSE4855Ja&default-theme=true
RNS Number : 4855J Hutchmed (China) Limited 05 April 2024
Press Release
HUTCHMED Highlights Data to be Presented at AACR Congress 2024
Hong Kong, Shanghai & Florham Park, NJ - Friday, April 5, 2024: HUTCHMED
(China) Limited ("HUTCHMED (https://www.hutch-med.com/) ") (Nasdaq/AIM:HCM;
HKEX:13) today announces that new and updated data from several studies of
compounds discovered by HUTCHMED will be presented at the upcoming American
Association of Cancer Research ("AACR") Annual Meeting 2024, taking place on
April 5-10, 2024 in San Diego, California.
Initial preclinical data will be presented for HMPL-506, a novel, highly
potent and differentiated menin-MLL inhibitor for the treatment of certain
types of acute leukemia. Compared with five other menin inhibitors in clinical
development, HMPL-506 showed the stronger inhibitory potency in MLL-rearranged
and NPM1 mutant leukemia cell line models. Furthermore, HMPL-506 in
combination with azacytidine, venetoclax or gilteritinib synergistically
improved the anti-tumor effect against MLL-rearranged leukemias both in vitro
and in vivo. The investigational drug candidate displayed favorable
pharmacokinetic profiles, high selectivity and low risk of cardiac toxicity. A
Phase I study of HMPL-506 is planned for the second half of 2024.
Initial preclinical data will also be presented for HMPL-A067 (HMA800067), a
novel CD38-targeting antibody-drug conjugate (ADC) in which daratumumab was
conjugated with cytotoxic payload Monomethyl auristatin E (MMAE) via a novel
linker. It demonstrated significant superior anti-tumor activity to
daratumumab, including in several B-cell malignancies models with resistance
to daratumumab treatment.
Other presentations include preclinical data on the ERK 1/2 inhibitor,
HMPL-295; early clinical data on the Syk inhibitor, sovleplenib, in lymphoma
patients; additional clinical data from global studies of VEGFR inhibitor,
fruquintinib, and MET inhibitor, savolitinib; and several
investigator-initiated studies of fruquintinib and VEGFR/CSF-1R/FGFR
inhibitor, surufatinib.
Details of the presentations are as follows:
Abstract title Presenter / Lead author Presentation details
SPONSORED STUDIES
HMPL-506, a novel, highly potent and differentiated menin-MLL inhibitor for Min Cheng, HUTCHMED, Shanghai, China #2113 (https://www.abstractsonline.com/pp8/#!/20272/presentation/8053)
the treatment of MLL-rearranged and NPM1mutant acute leukemia in preclinical
models Poster Session (PO.ET07.02 - Pharmacodynamic Biomarkers of Drug Response)
Monday, April 8, 2024
HMPL-A067 (HMA800067), a novel CD38-targeting antibody-drug conjugate (ADC), Yan Xu, HUTCHMED, Shanghai, China #1890 (https://www.abstractsonline.com/pp8/#!/20272/presentation/1123)
demonstrated superior anti-tumor activity to daratumumab in preclinical B-cell
malignancies models Poster Session (PO.ET01.02 - Antibody-Drug Conjugates and Bispectific
Antibodies)
Monday, April 8, 2024
Preclinical characterization of HMPL-295, a potent and selective ERK1/2 Jia Hu, HUTCHMED, Shanghai, China #1661 (https://www.abstractsonline.com/pp8/#!/20272/presentation/7717)
inhibitor
Poster Session (PO.MCB03.01 - Cell Signaling Components as Therapeutic
Targets)
Monday, April 8, 2024
Targeting YAP1/TEAD signaling re-sensitizes MAPK/ERK pathway inhibitors in Xianwen Yang, HUTCHMED, Shanghai, China #1931 (https://www.abstractsonline.com/pp8/#!/20272/presentation/3297)
KRAS-driven cancer cells
Poster Session (PO.ET03.04 - Drug Resistance 2: Ras GTPase)
Monday, April 8, 2024
Safety and Efficacy of Sovleplenib (HMPL-523), a Syk Inhibitor, in Patients Paolo Strati, The University of Texas MD Anderson Cancer Center, USA #CT144 (https://www.abstractsonline.com/pp8/#!/20272/presentation/11511)
with Relapsed or Refractory Lymphoma
Poster Session (PO.CT01.03 - Phase 0 and Phase I Clinical Trials)
Monday, April 8, 2024
Early carcinoembryonic antigen (CEA) dynamics to predict the efficacy of Stefano Lonardi, Veneto Institute of Oncology IOV-IRCCS Padua, Italy #6408 (https://www.abstractsonline.com/pp8/#!/20272/presentation/2118)
fruquintinib (F) + best supportive care (BSC) in patients with metastatic
colorectal cancer (mCRC) enrolled in FRESCO-2 Poster Session (PO.CL01.10 - Predictive Biomarkers 5)
Tuesday, April 9, 2024
Savolitinib (savo) + osimertinib (osi) vs savo + placebo (PBO) in patients James Chih-Hsin Yang, National Taiwan University Hospital and National Taiwan #CT251 (https://www.abstractsonline.com/pp8/#!/20272/presentation/11572)
(pts) with EGFR-mutated (EGFRm), MET-amplified advanced NSCLC with progression University Cancer Centre, Taipei, Taiwan
on osi Poster Session (PO.CL01.10 - Predictive Biomarkers 5)
Tuesday, April 9, 2024
INVESTIGATOR-INITIATED STUDIES
Enhanced anticancer efficacy via ROS-dependent ferroptosis: synergy between Xiaolin Li, First Affiliated Hospital of Nanjing Medical University, Nanjing, #2122 (https://www.abstractsonline.com/pp8/#!/20272/presentation/8063)
surufatinib and cisplatin in small cell lung cancer China
Poster Session (PO.ET07.02 - Pharmacodynamic Biomarkers of Drug Response)
Monday, April 8, 2024
Efficacy and underlying mechanisms of surufatinib in non-small cell lung Yanfang Zheng, Affiliated Cancer Hospital & Institute of Guangzhou Medical #2126 (https://www.abstractsonline.com/pp8/#!/20272/presentation/8068)
cancer treatment University, Guangzhou, China
Poster Session (PO.ET07.02 - Pharmacodynamic Biomarkers of Drug Response)
Monday, April 8, 2024
Enhancing Radiosensitivity in Biliary Tract Cancer: The Dual Role of Hong Ma, Wuhan Union Hospital, Wuhan, China #2127 (https://www.abstractsonline.com/pp8/#!/20272/presentation/8069)
Surufatinib in Tumor Suppression and Macrophage Reprogramming
Poster Session (PO.ET07.02 - Pharmacodynamic Biomarkers of Drug Response)
Monday, April 8, 2024
Surufatinib treatment in pancreatic cancer: unveiling the role of GPR34 in Jihui Hao / Song Gao, Tianjin Medical University Cancer Institute and #2128 (https://www.abstractsonline.com/pp8/#!/20272/presentation/8070)
TAMs and enhancing immunotherapy efficacy Hospital, Tianjin, China
Poster Session (PO.ET07.02 - Pharmacodynamic Biomarkers of Drug Response)
Monday, April 8, 2024
Efficacy and Underlying Mechanisms of Surufatinib Combined with PD-1 Guanghai Dai / Ru Jia, Chinese PLA General Hospital (CPLAGH), Beijing, China #2129 (https://www.abstractsonline.com/pp8/#!/20272/presentation/8071)
Monoclonal Antibody and Chemotherapy in Pancreatic Cancer
Poster Session (PO.ET07.02 - Pharmacodynamic Biomarkers of Drug Response)
Monday, April 8, 2024
Optimizing the treatment schedule of radiotherapy combined with VEGFR-TKIs and Tao Zhang / Zhenyu Lin, Cancer Center, Union Hospital Tongji Medical College, #3827 (https://www.abstractsonline.com/pp8/#!/20272/presentation/1789)
PD-(L) 1 inhibitors in metastatic colorectal cancer Huazhong University of Science and Technology, Wuhan, China
Poster Session (PO.CL10.04 - Outcome Investigation with Real World Data)
Monday, April 8, 2024
Clinical and epidemiological profile of neuroendocrine differentiation- A Susheng Shi / Yaru Wen, Cancer Hospital Chinese Academy of Medical Sciences, #4630 (https://www.abstractsonline.com/pp8/#!/20272/presentation/8300)
hospital-based retrospective study Beijing, China
Poster Session (PO.ET06.04 - Molecular Classification of Tumors for
Diagnostics, Prognostics, and Therapeutic Outcomes)
Tuesday, April 9, 2024
Epidemiological characteristics and treatment strategies of gastric cancer Jun Zhang, The First Affiliated Hospital of Chongqing Medical University, #4864 (https://www.abstractsonline.com/pp8/#!/20272/presentation/4864)
with neuroendocrine differentiation (NED) Chongqing, China
Poster Session (PO.PS01.08 - Descriptive Epidemiology and Statistical and
Epidemiological Methodology)
Tuesday, April 9, 2024
Initial efficacy of surufatinib plus sintilimab and IBI310 for patients with Lin Shen / Ming Lu, Peking University Cancer Hospital and Institute, Beijing, #CT266 (https://www.abstractsonline.com/pp8/#!/20272/presentation/11587)
high-grade advanced-neuroendocrine neoplasm: A multicenter, single arm phase 2 China
study Poster Session (PO.CT02.02 - Phase II Clinical Trials 2)
Tuesday, April 9, 2024
About HUTCHMED
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage,
biopharmaceutical company. It is committed to the discovery, global
development and commercialization of targeted therapies and immunotherapies
for the treatment of cancer and immunological diseases. It has approximately
5,000 personnel across all its companies, at the center of which is a team of
about 1,800 in oncology/immunology. Since inception, HUTCHMED has focused on
bringing cancer drug candidates from in-house discovery to patients around the
world, with its first three medicines marketed in China, the first of which is
also marketed in the U.S. For more information, please visit:
www.hutch-med.com (http://www.hutch-med.com) or follow us on LinkedIn
(https://www.linkedin.com/company/hutchmed/) .
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of
the "safe harbor" provisions of the U.S. Private Securities Litigation Reform
Act of 1995. These forward-looking statements reflect HUTCHMED's current
expectations regarding future events, including but not limited to its
expectations regarding the therapeutic potential of fruquintinib, savolitinib,
surufatinib, sovleplenib, HMPL-295, HMPL-506 and HMA800067, the further
clinical development for fruquintinib, savolitinib, surufatinib, sovleplenib,
HMPL-295, HMPL-506 and HMA800067, its expectations as to whether any studies
on fruquintinib, savolitinib, surufatinib, sovleplenib, HMPL-295, HMPL-506 and
HMA800067 would meet their primary or secondary endpoints, and its
expectations as to the timing of the completion and the release of results
from such studies. Such risks and uncertainties include, among other things,
assumptions regarding enrollment rates and the timing and availability of
subjects meeting a study's inclusion and exclusion criteria; changes to
clinical protocols or regulatory requirements; unexpected adverse events or
safety issues; the ability of fruquintinib, savolitinib, surufatinib,
sovleplenib, HMPL-295, HMPL-506 and HMA800067, including as combination
therapies, to meet the primary or secondary endpoint of a study, to obtain
regulatory approval in different jurisdictions and to gain commercial
acceptance after obtaining regulatory approval; the potential markets of
fruquintinib, savolitinib, surufatinib, sovleplenib, HMPL-295, HMPL-506 and
HMA800067 for a targeted indication, and the sufficiency of funding. In
addition, as certain studies rely on the use of nab-paclitaxel, sintilimab,
toripalimab, pemetrexed, platinum, etoposide or cisplatin as combination
therapeutics, such risks and uncertainties include assumptions regarding their
safety, efficacy, supply and continued regulatory approval. Existing and
prospective investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof. For
further discussion of these and other risks, see HUTCHMED's filings with the
U.S. Securities and Exchange Commission, The Stock Exchange of Hong Kong
Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the
information contained in this press release, whether as a result of new
information, future events or circumstances or otherwise.
Medical Information
This press release contains information about products that may not be
available in all countries, or may be available under different trademarks,
for different indications, in different dosages, or in different strengths.
Nothing contained herein should be considered a solicitation, promotion or
advertisement for any prescription drugs including the ones under development.
CONTACTS
Investor Enquiries +852 2121 8200 / ir@hutch-med.com (mailto:ir@hutch-med.com)
Media Enquiries
Ben Atwell / Alex Shaw, FTI Consulting +44 20 3727 1030 / +44 7771 913 902 (Mobile) /
+44 7779 545 055 (Mobile) / HUTCHMED@fticonsulting.com
(mailto:HUTCHMED@fticonsulting.com)
Zhou Yi, Brunswick +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
(mailto:HUTCHMED@brunswickgroup.com)
Nominated Advisor
Atholl Tweedie / Freddy Crossley / Daphne Zhang, Panmure Gordon +44 (20) 7886 2500
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END NRAIAMRTMTTMMPIRecent news on HUTCHMED (China)
See all newsREG - Hutchmed China Ltd - Positive CHMP Opinion for Fruquintinib
AnnouncementREG - Hutchmed China Ltd - Vesting of Awards Under the LTIP
AnnouncementREG - Hutchmed China Ltd - 2023 Annual Report and Notice of AGM
AnnouncementRCS - Hutchmed China Ltd - Data to be Presented at AACR Congress 2024
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED and Innovent Announce NDA Acceptance
Announcement